Lung Cancer Drug Trial Missed Primary Goal
The FURVENT study failed to show progression-free survival benefits for patients with non-small cell lung cancer.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should medical drug trials be deemed successful if they miss primary goals but show secondary improvements?
ArriVent BioPharma announced that its Phase 3 trial for the drug firmonertinib failed to reach its primary efficacy endpoint in patients with non-squamous non-small cell lung cancer. The trial was aimed at establishing the drug as a first-line treatment for these patients.
Why it matters
This outcome impacts the potential landscape for first-line lung cancer treatments, as the drug failed to meet its target for improving progression-free survival compared to chemotherapy. The company is now reviewing data to decide on the future of the drug's development.
In the FURVENT Phase 3 trial involving 398 previously untreated patients, firmonertinib did not meet its primary endpoint of progression-free survival when compared against standard platinum-based chemotherapy combined with pemetrexed.
The players
ArriVent BioPharma
A biopharmaceutical company headquartered in Newtown Square, PA, focused on developing targeted lung cancer therapies.
The details
The study evaluated firmonertinib at daily oral doses of 160 milligrams and 240 milligrams. Researchers compared outcomes using blinded independent central review. While the trial did not reach its efficacy goal, it monitored treatment-emergent adverse events of Grade 3 or higher, which occurred at rates of 52% and 53% in the drug arms compared to 55% in the chemotherapy control group.
Timeline
October 14, 2026: ArriVent BioPharma reported the Phase 3 trial failure.
Health Landscape
The FURVENT Phase 3 trial failure interrupts the expected development timeline for this targeted therapy in first-line lung cancer treatment. While firmonertinib remains approved in China for specific advanced EGFR-mutated cases, its efficacy in untreated populations remains in question.
This development does not change current care, but it serves as a reminder to consult with an oncologist regarding the latest trial results when discussing treatment options for non-small cell lung cancer. Patients currently navigating treatment decisions should speak with their doctor about proven, standard-of-care options.
The takeaway
This trial result underscores the ongoing complexities of developing targeted therapies for non-small cell lung cancer. When considering clinical trials, always discuss the most recent efficacy data and trial status with your oncology care team.
Further reading
For more information on current treatment standards, visit the Cancer section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Should medical drug trials be deemed successful if they miss primary goals but show secondary improvements?
